SOURCES SOUGHT
B -- Plasma tau as a biomarker and risk factor for pathogenic brain changes in non-demented adults
- Notice Date
- 4/27/2021 8:42:22 AM
- Notice Type
- Sources Sought
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95021Q00155
- Response Due
- 5/12/2021 7:00:00 AM
- Archive Date
- 05/27/2021
- Point of Contact
- Karen Mahon
- E-Mail Address
-
Karen.Mahon@nih.gov
(Karen.Mahon@nih.gov)
- Description
- This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.� It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.� Responses will not be considered as proposals or quotes.� No award will be made as a result of this notice.� The Government will NOT be responsible for any costs incurred by the respondents to this notice.� This notice is strictly for research and information purposes only. Background:� Given the putative role of tau phosphorylation, destabilization, and aggregation in Alzheimer�s disease pathogenesis, understanding the biological processes that promote pathological tau formation is essential. The association between amyloid-beta (A� ) and early p-tau accumulation has been established, supporting the theory that amyloidosis can lead to hyperphosphorylation of pathogenic tau isoforms. In addition, evidence that peripheral inflammatory/immune and hemostatic/vascular processes may act as molecular drivers of tau pathology has recently emerged. Using available data from the Baltimore Longitudinal Study of Aging (BLSA), we have the unique opportunity to apply a proteome-wide discovery approach to identify peripherally-acting molecular drivers of tau progression. In doing so, we will learn about the systemic biological processes that may influence tau progression. Results will point to new therapeutic avenues for slowing pathogenic tau in those at risk for Alzheimer�s disease. To further understand the peripheral processes that may accelerate pathological tau formation within the brain, we will use stored plasma from 700 participants to conduct a comprehensive proteomic measurement using Olink technology and examine whether baseline expression of circulating plasma proteins and identified protein networks predict longitudinal increases in plasma p-tau181 and PET-defined tau neurofibrillary tangles (NFTs).� Purpose and Objectives: The purpose of this requirement is to utilize a discovery-based proteomics platform in archived plasma samples collected in the Baltimore Longitudinal Study of Aging (BLSA) to identify molecular pathways that accelerate pathological phosphorylation of tau in individuals at risk for AD. Project requirements: The Contractor shall perform discovery-based proteomic assays on 700 human plasma samples from the BLSA cohort and generate proteome-wide measurement information for each participant. NIA instigators will use protein measurements to identify molecular pathways that accelerate pathological phosphorylation of tau in individuals at risk for AD. Anticipated period of performance: 3 months Other important considerations: The Contractor must perform analysis compatible with previously acquired Olink analytes. Capability statement /information sought. Respondents must provide, as part of their responses, a capability statement that includes: (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; (e) examples of prior completed Government contracts, references, and other related information; and (f) how their solution is compatible with Olink analytes. The respondent must also provide their� DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein.� A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit.� The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents� technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer.� Facsimile responses are NOT accepted. The response must be submitted to Karen Mahon at e-mail address karen.mahon@nih.gov. The response must be received on or before May 12, 2021 at 10:00 am, Eastern Time. �Disclaimer and Important Notes:� This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).�
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/f9d8e05cc0474c7588c57decf40400ce/view)
- Record
- SN05984789-F 20210429/210427230115 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |